0001193125-26-199065
SEC filingA challenging quarter marked by a 3% revenue decline and widening operating losses, as the company's largest customer transitioned testing in-house. However, positive free cash flow of $1.9M provides a buffer for ongoing strategic investments.
Fulgent Genetics reported Q1 FY2026 revenue of $71.1M, a 3% decline from the prior year period. The decrease in precision diagnostics revenue was driven by the decline in revenue from our largest customer as this customer begins to perform tests internally. This volume reduction created immediate margin pressure, with gross profit falling 24% to $21.5M. The resulting gross margin of 30.2% reflects the impact of reduced scale on the company's cost structure. Geographically, the company saw increases in revenue to Australia and Canada, partially offset by a decrease in revenue to the United Kingdom.
Operating income declined to -$34.6M from -$19.8M in the prior year, a 75% increase in the operating loss. The operating margin of -48.7% indicates that operating expenses remained elevated relative to the reduced revenue base. Net loss widened to -$24.8M compared to -$11.5M in Q1 FY2025. The company continues to maintain strategic investments despite the revenue headwinds, as management navigates the transition of its largest customer relationship while pursuing growth in other market segments.
A notable bright spot was the improvement in cash generation. Net cash provided by operating activities was $7.1M, a significant improvement from -$4.4M in the prior year period. The increase in cash provided from operating activities was primarily due to the timing of cash receipts from customers and cash payments for operating expenses, including bonus expenses. Capital expenditures totaled $5.2M, resulting in positive free cash flow of $1.9M. This cash flow inflection demonstrates the company's ability to manage working capital effectively during a period of revenue transition.